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Genome wide association studies (GWAS) and large scale replication studies have identified 
common variants in 79 loci associated with breast cancer, explaining ~14% of the familial risk of 
the disease. To identify new susceptibility loci, we performed a meta-analysis of 11 GWAS 
comprising of 15,748 breast cancer cases and 18,084 controls, and 46,785 cases and 42,892 
controls from 41 studies genotyped on a 200K custom array (iCOGS). Analyses were restricted to 
women of European ancestry. Genotypes for more than 11M SNPs were generated by imputation 
using the 1000 Genomes Project reference panel. We identified 15 novel loci associated with 
breast cancer at P<5x10-8. Combining association analysis with ChIP-Seq data in mammary cell 
lines and ChIA-PET chromatin interaction data in ENCODE, we identified likely target genes in two 
regions: SETBP1 on 18q12.3 and RNF115 and PDZK1 on 1q21.1. One association appears to be 
driven by an amino-acid substitution in EXO1. 
 
Breast cancer is the most common cancer in women worldwide1. The disease aggregates in families, 
and has an important inherited component. This inherited component is driven by a combination of 
rare variants, notably in BRCA1, BRCA2, PALB2, ATM and CHEK2 conferring a moderate or high 
lifetime risk of the disease, , together with common variants at more than  70 loci, identified through 
GWAS  and large scale replication studies2-20. Taken together, these loci explain approximately one-
third of the excess familial risk of breast cancer. 
The majority of susceptibility SNPs has been identified through the Breast Cancer Association 
Consortium (BCAC), a collaboration involving more than 50 case-control studies. We recently 
reported the results of a large-scale genotyping experiment within BCAC, which utilised a custom 
array (iCOGS) designed to study variants of interest for breast, ovarian and prostate cancers. iCOGS 
comprised more than 200,000 variants, of which 29,807 had been selected from combined analysis 
of nine breast cancer GWAS involving 10,052 breast cancer cases and 12,575 controls of European 
ancestry. In total, 45,290 breast cancer cases and 41,880 controls of European ancestry from 41 
studies were genotyped with iCOGS, leading to the discovery of 41 novel susceptibility loci16. A 
parallel analysis  identified four loci specific to oestrogen receptor (ER)-negative disease17 . However, 
additional susceptibility loci may have been missed because they were not selected from the original 
GWAS, or not included on the array.  
Genotype imputation is a powerful approach to infer missing genotypes using the genetic 
correlations defined in a densely genotyped reference panel, thus providing the opportunity to 
identify novel susceptibility variants even if not directly genotyped21. In this analysis we aimed to 
identify additional breast cancer susceptibility loci by utilising data from all 200k variants on the 
iCOGS array, and used imputation to estimate genotypes for more than 11M SNPs. We applied the 
same approach to data from 11 GWAS. After quality control (QC) exclusions, the dataset comprised 
15,748 breast cancer cases and 18,084 controls from GWAS, and 46,785 cases and 42,892 controls 
from 41 studies genotyped with iCOGS (see Online Methods and Supplementary Tables 1a-1e). All 
subjects were women of European ancestry.   
We imputed genotypes using the 1000 Genomes Project March 2012 release as the reference 
dataset (see Online Methods) The main analyses were based on ~11.6M SNPs that were imputed 
with imputation r2 >0.3 and had MAF>0.005 in at least one of the datasets22. 
 Of common SNPs (MAF>0.05), 88%  were imputed from the iCOGS array with r2>0.5; this compared 
to 99% of variants for the largest GWAS (UK2), which was genotyped using a 670k SNP array (Figure 
1a and 1b, Supplementary Table 2). Thirty-seven per cent of common SNPs were imputed on the 
iCOGS with r2>0.9 , compared with 85% for UK2. Thus, despite being designed as a follow-up of 
GWAS for different diseases rather than a genome-wide array, the majority of common variants 
could be imputed using the iCOGS, but the overall imputation quality was, poorer that from a 
standard GWAS array. Imputation quality decreased with decreasing allele frequency (Figure 1c and 
1d, Supplementary Table 2).  
Log odds ratio estimates and standard errors were calculated for each dataset using logistic 
regression, adjusting for principal components where it was found to reduce substantially the 
inflation factor. We then combined the results from each dataset for variants with MAF >0.5% using 
a fixed effects meta-analysis23. More than 7,000 variants with a combined P<5x10-8 for association 
were identified, the large majority of which was in regions previously shown to be associated with 
breast cancer susceptibility. Of the 79 previously published breast cancer susceptibility loci identified 
in women of European ancestry, all but eight show evidence of association at P<5x10-8 for overall, 
ER-positive or ER-negative disease risk (Supplementary Tables 3a, 3b and 3c). For four of the eight 
variants, (rs1550623 on 2q31, rs11571833 on 13q13.1, rs12422552 on 12p13.1 and rs11242674 on 
6p25.3), slightly weaker evidence of association was observed. One reported variant, rs7726159 did 
not reach P<5x10-8 in this (P=0.0017) or the previous analysis – it was identified through fine-
mapping of the TERT region on 5p15.3318. One other variant in AKAP9, rs6964587 reported 
previously19 did not reach P<5x10-8 but an alternative correlated with it did (P=3.67x10-8 for 
chr7:91681597:D; r2 between the two markers = 0.98).  The two remaining variants (rs2380205 on 
10p15 and rs1045485 at CASP8) were reported in earlier analysis9,24 but did not even reach 
P<0.0001, suggesting that they may have been false positive reports. An alternative variant at 
CASP8, rs1830298 (r2=0.06, D’=1 with rs1045485 in 1000G CEU) did reach P<5x10-8 in this dataset25.   
To assess evidence for additional susceptibility loci, we removed all SNPs within 500kb of 
susceptibility variants identified previously in women of European ancestry2-14,16-19, leaving 314 
variants from 27 regions associated with breast cancer at P<5x10-8 (Supplementary Figures 1 and 2). 
The strongest associations were observed in a 610kb (b37 28,314,612- 28,928,858) interval on 
chromosome 22 (smallest P=8.2x10-22, for rs62237573). This interval lies approximately 100kb 
centromeric to CHEK2, and further analysis revealed that the associated SNPs were correlated with 
the CHEK2 founder variant 1100delC (strongest correlation r2=0.39 for SNP rs62235635),  CHEK2 
1100delC is known to be associated with breast cancer through candidate gene analysis, but has not 
previously generated an association in GWAS  26,27. We performed an analysis adjusting for CHEK2 
1100delC using data on ~40,000 samples that had been genotyped for this variant. The strongest 
associated variant in this subset was rs140914118; after adjustment for 1100delC the statistical 
significance diminished markedly (P=3.1x10-9 to P=0.78;Supplementary Figures 3a and 3b), 
suggesting that this signal is driven by CHEK2 1100delC. 
Variants in four regions (DNAJC1, 5p12, PTHLH and MKL1) lay within 2Mb of a previously published 
susceptibility-associated SNP. In each case, these associations became weaker (no longer P<5x10-8) 
after adjustment for the previously associated SNP(s) in the region (data not shown). For four other 
regions, the significant variants were identified in just one GWAS, and failed imputation (r2<0.3) in 
the remaining datasets, including iCOGS;  we did not consider these variants further.  
To confirm the results for the remaining 18 regions, we performed re-imputation in the iCOGS 
dataset without phasing (See Online Methods). Fifteen loci remained associated with breast cancer 
at P<5x10-8 (Table 1 and Supplementary Table 4). For three of the loci, the most significant SNP, or a 
highly correlated SNP, had been directly genotyped on iCOGS (Supplementary Table 5); one, 
rs11205277, had been included on the array because it is associated with adult height28, while the 
other two were selected based on evidence from the combined breast cancer GWAS but failed to 
reach genome-wide significance in the earlier analyses. We attempted to genotype the 12 remaining 
variants on a subset of ~4K samples  to confirm the quality of the imputation (10 variants could be 
directly genotyped, for one region an alternative correlated variant was selected (Supplementary 
Table 5). For the 11 variants that could be assessed, the r2 between the observed and imputed 
genotypes were close to the r2 estimated in the imputation. Furthermore, the estimated effect sizes 
in the subset of individuals that we genotyped were similar to those obtained from the imputed 
genotypes (Supplementary Table 5). These results indicate that the analyses based on imputed 
genotype data were reliable. 
There was little or no evidence of heterogeneity in the per-allele odds ratios (ORs) among studies 
genotyped using iCOGS (Supplementary Table 6 and Supplementary Figure 4). There was little 
evidence for departure from a log-additive model for any locus, except for a borderline departure for 
rs6796502 (P=0.049) for which the ORs for heterozygotes and homozygotes for the risk associated 
allele were similar (Supplementary Table 6). 
The estimated ORs for invasive versus in-situ disease were similar for all the loci (P>0.05) 
(Supplementary Table 7). For four of the loci, rs12405132, rs12048493, rs4593472 and rs6507583 
the association was stronger for ER positive disease (case only P<0.05) (Supplementary Table 8). 
Seven of the loci were associated with ER-negative disease (P<0.05) but none had a stronger 
association for ER-negative than ER-positive disease. Two of the loci showed significant trends in the 
OR by age at diagnosis: for rs13162653, the OR was higher at younger ages (P=0.007), while for 
rs6507583, the OR was higher at older ages (P=0.006) (Supplementary Table 9). One of the variants, 
chr17:29230520:D in ATAD5 is correlated with a variant that has also been shown to be associated 
with serous ovarian cancer in a meta-analysis29 (r2=0.93 between chr17:29230520:D and 
chr17:29181220:I).  
To approach the task of identifying the likely causal variants and genes underlying these 
associations, we first defined the set of all SNPs correlated with each of the 15 lead SNPs and that 
could not be ruled out as potentially causal (based on a likelihood ratio 100:130), resulting in a subset 
of 522 variants (Supplementary Table 10). One of the variants, rs72755295, lies in an intron of EXO1, 
encoding a protein involved in mismatch repair. It is strongly correlated with only one other variant, 
rs4149909, coding for an amino-acid substitution in EXO1 (p.Asn279Ser; CADD score 3331), 
suggesting that this variant is likely to be functionally related to breast cancer risk. None of the 
remaining SNPs lay within gene coding sequences, consistent with previous observations that most 
common cancer susceptibility variants are regulatory. For each of the remaining 520 variants, we 
then looked for enhancer elements in mammary cell lines, based on ENCODE ChIP-Seq data32,33. To 
identify potential gene targets, we combined this information with ENCODE ChIA-PET chromatin 
interaction data. We identified two regions in which the associated variants overlapped with 
putative enhancer sequences and for which consistent promoter interactions were predicted (Table 
1). For rs12405132 at 1q21.1 , we identified four potential interacting genes, RNF115, POLR3C, PDZK1 
and PIAS3 (Figure 2). Of these, the strongest evidence was for RNF115 and PDZK1; three of the 64 
potentially causal variants lay in interacting enhancer regions. RNF115 (also known as BCA2) is an E3 
ubiquitin ligase RING finger protein that is overexpressed in ER-positive breast cancers34. PDZK1 is a 
scaffold protein that connects plasma membrane proteins and regulatory components, regulating 
their surface expression in epithelial cells apical domains, and has been proposed to act as an 
oncogene in breast cancer35.  
SNPs correlated with rs6507583 at 18q12.3 lay in regions interacting with the promoter of SETBP1 
(Supplementary Figure 5). The encoded protein has been shown to bind the SET nuclear oncogene 
which is involved in DNA replication.  
We utilised data from TCGA to assess associations between the 15 novel susceptibility variants and 
expression of neighbouring genes in breast tumors and normal breast tissue. One SNP, rs7707921, 
was strongly associated with RPS23 expression in all tissues (Supplementary Table 11, 
Supplementary Figure 6). However, stronger associations with expression were observed with more 
telomeric SNPs that were less strongly associated with disease risk (top eQTL SNP rs3739: P=10-23, P-
risk=5.28x10-7), suggesting that this association may be coincidental. SNP, rs7707921 was also more 
weakly associated with expression of ATP6AP1L (P=5.6x10-5 in tumours, P=0.066 in normal tissue).  
Based on the estimated ORs in the iCOGS stage (all but one of which were in the range 1.05-1.10), 
the 15 novel loci identified here would explain a further ~2% of the 2-fold familial risk of breast 
cancer. Taken together with previously identified loci, more than 90 independent common 
susceptibility loci for breast cancer have been identified, explaining ~16% of the familial risk. We 
estimate assuming a log-additive model that, based on genotypes for variants at these loci, 
approximately 5% of women in the general population have a >2 fold increased risk of breast cancer 
and 0.7% of women have  a >3 fold increased risk. In the current analyses, more than 50% of variants 
with MAF>0.005 in subjects of European ancestry were well imputable (r2>0.5) These results suggest 
that, while there may be further susceptibility variants with comparable associated effects that were 
not well imputed, the identification of many additional loci will require larger association studies. In 
the meantime, inclusion of these additional loci in polygenic risk scores will improve our ability to 
discriminate between high and low risk individuals, potentially improving breast cancer screening 
and prevention. 
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Figure Legends 
Figure 1: Histograms of the imputation r2 a) Histogram of the imputation r2 for the iCOGS for variants 
with MAF>0.05 b) Histogram of the imputation r2 for the UK2 GWAS for variants with MAF>0.05 c) 
Histogram of the imputation r2 for the iCOGS for variants with MAF<=0.05 d) Histogram of the 
imputation r2 for the UK2 GWAS for variants with MAF<=0.05. 
Figure 2: The chromosome 1 locus tagged by rs12405132 a) The Manhattan Plot displays the 
strength of genetic association (-log10 P ) versus chromosomal position (Mb), where each dot 
presents a genotyped (solid black dot) or imputed (red circle) SNP (in the iCOGS stage). The purple 
horizontal line represents the threshold for genome-wide significance (P=5x10-8). Gene structures 
are depicted as well as the location of SNPs with MAF>0.01 which were neither imputed reliably nor 
genotyped. b) Mammary cell enhancer locations as defined in Corradin et al.32, and Hnisz et al.33, are 
shown where elements overlapping the best associated SNPs are labelled with their predicted target 
genes. A subset of ChiA-PET interactions in MCF7 cells (mediated by either RNApolII or ERa) between 
enhancers and their target gene promoters are also shown. 
  
 Best variant Locus Position
2 
Alleles
3 
EAF
4 
r
2(5)
 GWAS OR 
(95% CI)
6 
GWAS P
7 
iCOGS OR 
(95% CI) 
iCOGS P Combined 
GWAS + 
 iCOGS P  
Genes within 
+/-2kb 
Enhancers in 
MCF7/HMEC 
eQTLs 
rs12405132 1q21.1 145644984 C/T 0.36 0.96 0.96 
(0.92-0.99) 
0.00962 0.95 
(0.93-0.97) 
2.34x10
-7 
7.92x10
-9 
LOC10028814, 
NBPF10, 
RNF115 
RNF115, 
POLR3C,PDZK1, 
PIAS3 
- 
rs12048493 1q21.2 149927034 A/C 0.34 0.76 1.04 
(0.99-1.09) 
0.121 1.07 
(1.05-1.10) 
1.66x10
-9 
1.10x10
-9 
- - - 
rs72755295
 
1q43 242034263 A/G 0.03 0.94 1.19 
(1.03-1.39) 
0.021 1.15 
(1.09-1.22) 
2.60x10
-7 
1.82x10
-8 
EXO1 - - 
rs6796502 3p21.3 46866866 G/A 0.09 0.91 0.92 
(0.87-0.98) 
0.00657 0.92 
(0.89-0.95) 
8.13x10
-7 
1.84x10
-8 
- - - 
rs13162653 5p15.1 16187528 G/T 0.45 0.72 0.92 
(0.88-0.95) 
5.18x10
-6
 0.95 
(0.93-0.97) 
1.71x10
-6 
1.08x10
-10 
- - - 
rs2012709 5p13.3 32567732 C/T 0.46 0.81 1.06 
(1.02-1.09) 
0.00101 1.05 
(1.03-1.08) 
1.66x10
-6 
6.38x10
-9 
- - - 
rs7707921 5q14 81538046 A/T 0.23 0.88 0.94 
(0.9-0.98) 
0.00302 0.93 
(0.91-0.95) 
4.09x10
-9 
5.00x10
-11 
ATG10 - RPS23, 
ATP6AP1L 
 rs9257408 6p22.1 28926220 G/C 0.38 0.92 1.05 
(1-1.1) 
0.0372 1.05 
(1.03-1.08) 
4.53x10
-7 
4.84x10
-8 
- - - 
rs4593472 7q32.3 130667121 C/T 0.35 1.00 0.92 
(0.88-0.96) 
2.57x10
-5 
0.95 
(0.94-0.97) 
3.97x10
-6 
1.83x10
-9 
FLJ43663 - - 
rs13365225 8p11.23 36858483 A/G 0.17 0.94 0.89 
(0.85-0.93) 
6.32x10
-7 
0.95 
(0.93-0.98) 
0.000159 1.06x10
-8 
- - - 
rs13267382 8q23.3 117209548 G/A 0.36 0.97 1.07 
(1.03-1.12) 
0.000537 1.05 
(1.03-1.07) 
4.87x10
-6 
1.72x10
-8 
LINC00536 - - 
rs11627032 14q32.12 93104072 T/C 0.26 0.73 0.94 
(0.9-0.98) 
0.00114 0.94 
(0.92-0.96) 
1.06x10
-6 
4.48x10
-9 
RIN3 - - 
chr17:29230520
:D 
17q11.2 29230520 GGT/G 0.20 0.77 0.94 
(0.89-0.98) 
0.009 0.93 
(0.91-0.96) 
1.11x10
-6 
3.34x10
-8 
ATAD5 - - 
rs745570 17q25.3 77781725 A/G 0.50 0.93 0.94 
(0.91-0.98) 
0.000754 0.95 
(0.93-0.97) 
4.52x10
-7 
1.40x10
-9 
- - - 
rs6507583 18q12.3 42399590 A/G 0.07 0.96 0.91 
(0.85-0.98) 
0.00803 0.91 
(0.88-0.95) 
1.21x10
-6 
3.20x10
-8 
SETBP1 SETBP1 - 
 Table 2: Results for the 15 regions with combined P<5x10-8. Results are shown for the strongest associated variant in the region. 
1 
Chromosome 
2 
Build 37 position 
3 
Reference/effect allele, based on the forward strand  
4
 Mean effect allele frequency over all controls 
5
 Imputation r
2 
in the iCOGS samples (calculated by the average info score from IMPUTEv2) 
6 
Per allele odds ratio for the minor allele relative to the major allele 
7 
P value for the 1df trend test 
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Online Methods 
Details of the subjects, genotyping and QC measures for the GWAS and iCOGS data are described 
elsewhere12,14,16,36,37. All participating studies were approved by their appropriate ethics review 
board and all subjects provided informed consent. Analyses were restricted to women of European 
ancestry. All imputations were performed using the 1000 Genomes Project March 2012 release as 
the reference panel. Of the 11 GWAS, 8 (C-BCAC) plus a subset of the BPC3 GWAS (CGEMS) were 
used in the combined GWAS analysis that nominated 29,807 SNPs for the array. The BPC3 and 
TNBCC GWAS nominated additional SNPs with evidence for association with ER-negative or triple-
negative (ER-, PR- and HER2- negative) breast cancer. The EBCG GWAS was not used to nominate 
SNPs for the iCOGS array.  
For eight GWAS (C-BCAC), genotypes were imputed in a two-stage procedure, using SHAPEIT to 
derive phased genotypes and IMPUTEv2 to perform the imputation on the phased data 22. We 
performed the imputation using 5Mb non-overlapping intervals for the whole genome. OR estimates 
and standard errors where obtained using logistic regression with SNPTEST 21. For two of the studies 
we adjusted for the 3 leading principal components as it was found to reduce materially the inflation 
factor; for the rest of the studies no such adjustment was necessary. For the remaining three GWAS 
(BPC3, TNBCC and EBCG), imputation was performed using MACH and Minimac23.Genomic control 
adjustment was applied to each GWAS as previously described16. The iCOGS data were also imputed 
in a two-stage procedure using SHAPEIT and IMPUTEv2, again using 5Mb non-overlapping intervals. 
We split the ~90K samples into 10 subsets, where possible keeping subjects from the same study in 
the same subset. We obtained OR estimates and standard errors using logistic regression adjusting 
for study and 9 principal components.  
For the regions showing evidence of association we repeated the imputation in iCOGS, using 
IMPUTEv2 but without pre-phasing in SHAPEIT to improve imputation accuracy. We also increased 
the number of MCMC iterations from 30 to 90, and increased the buffer region from 250kb to 
500kb. 
Meta-analysis 
OR estimates and standard errors were combined in a fixed effects inverse variance meta-analysis 
using METAL23. For the GWAS, results were included in the analysis for all SNPs with MAF>0.01 and 
imputation r2>0.3, except for the TN GWAS where the criteria were r2>0.9 and MAF>0.05. For iCOGS, 
we included all SNPs with r2>=0.3 and MAF>0.005.  
Confirmatory genotyping  
The best variant in each region after the re-imputation and meta-analysis was genotyped in 4123 
samples from SEARCH, using Taqman according to the manufacturer’s instructions. The squared 
correlations between the observed genotypes and the genotypes estimated by imputation are 
shown in Supplementary Table 5. For all the imputed SNPs the squared correlations was greater 
than 0.7, the call-rates were >=0.98 and there was no evidence of departure of genotype 
frequencies from those expected under HWE (p>0.1).  
eQTL analyses 
Germline genotype, mRNA expression, and somatic copy number data for samples taken from breast 
tumours and tumour-adjacent normal tissue were obtained from The Cancer Genome Atlas38. The 
copy number and genotype data were measured using the Affymetrix Genome-Wide Human SNP 6.0 
platform. For the mRNA expression data, we used the expression profiles obtained using the Agilent 
G4502A-07-3 microarray. The genotype data were subjected to the following quality control filters. 
SNPs were excluded in case of low frequency (MAF < 1%), low call rate (< 95%,) or departure from 
Hardy-Weinberg equilibrium at P < 1 × 10−13. Individuals were excluded based on low call rate (< 
95%), or high heterozygosity (false discovery rate < 1%). Furthermore, individuals were also excluded 
in case of non-European ancestry, or male gender. Quality control and intersection with the other 
genomic data types resulted in 380 tumour samples and 56 normal samples. 
The genotype data were imputed as described above. eQTL analysis was performed using linear 
regression with SNPTEST, regressing the mRNA expression of selected candidate genes on the 
imputed genotype. For each gene, we performed the eQTL analysis against every microarray probe 
that uniquely maps to that gene. We adjusted the analyses for somatic copy number of the gene, 
and for SNPs that intersect the probe sequence, provided that their MAF exceeds 1% in individuals 
of European ancestry in the 1,000 Genomes data. 
Enhancer analyses 
Maps of enhancer regions with predicted target genes were obtained from Hnisz et al.33, and 
Corradin et al.32. Enhancers active in the mammary cell types MCF7, HMEC and HCC1954 were 
intersected with candidate causal variants using Galaxy. ENCODE ChIA-PET chromatin interaction 
data from MCF7 cells (mediated by RNApolII and ER) were downloaded using the UCSC Table 
browser. Galaxy was used to identify ChIA-PET interactions between an implicated mammary cell 
enhancer (containing a strongly associated variant) and a predicted gene promoter (defined as 
regions 3 kb upstream and 1 kb downstream of the transcription start site). 
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Supplementary Figure 1: Manhattan Plots for the strength of genetic association (-log10P) versus 
chromosomal position, where each dot represents a single variant. The association tests are from 
the meta-analysis of the GWAS and iCOGS datasets (see Online Methods). Variants within 500kb of 
variants previously established to be associated with breast cancer were removed (see text). Red 
horizontal line corresponds to the P=5x10-8, blue horizontal line corresponds to P=10-5. 
  

Supplementary Figure 2: Quantile-quantile plot of the observed vs. expected chi-squared statistics 
for the meta-analysis of the combined GWAS and iCOGS results. Variants within 500kb of previously 
established breast cancer susceptibility loci were removed. Each circle represents the chi-squared 
statistic for a single variant. The blue diagonal line represents the predicted association statistics 
under the global null hypothesis of no association. 
  

Supplementary Figure 3: a) Manhattan Plot of associations for the results in the CHEK2 region 
(chromosome 22, b37: 280,000,000-30,121,477), in the subset of individuals that had both iCOGS 
and the CHEK2*1100delC variant genotyped b) Manhattan Plot of associations for the (chromosome 
22, b37: 280,000,000-30,121,477) region, after adjusting for CHEK2*1100delC.  
  
a)
b)
Supplementary Figure 4: Forest plots for the 15 loci achieving genome-wide significance. Squares 
denote the estimated per-allele odds ratio for the minor allele in Europeans. The horizontal lines 
denote 95% confidence intervals. The area of the square is inversely proportional to the variance of 
the estimate. The diamond denotes the estimated per-allele OR from the combined analyses. I2 and 
heterogeneity P-values were calculated in the iCOGS studies alone.  
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Supplementary Figure 5: The chromosome 18 locus tagged by rs6507583 a) The Manhattan Plot 
displays the strength of genetic association (-log10 P) versus chromosomal position (Mb), where each 
dot presents a genotyped (solid black dot) or imputed (red circle) SNP (in the iCOGS stage). The 
purple horizontal line represents the threshold for genome-wide significance (P=5x10-8). Gene 
structures are depicted as well as the location of SNPs with MAF>0.01 which were neither imputed 
reliably nor genotyped. b) Mammary cell enhancer locations as defined in Corradin et al.33, and Hnisz 
et al.34, are shown where elements overlapping the best associated SNPs are labelled with their 
predicted target genes. A subset of ChiA-PET interactions in MCF7 cells (mediated by either RNApolII 
or ERa) between enhancers and their target gene promoters are also shown. 
 
  

 Supplementary Figure 6: Manhattan plots of association for the eQTL results (chromosome 5, b37: 
80,928,261-81,928,2611) in all breast cancer tumours, ER+, ER- tumours and normal from the TCGA 
data. The bottom plot represents the breast cancer meta-analysis risk results.   
 

Supplementary Table 1.  Studies contributing to the analysis. 
Supplementary Table 1a.  BCAC Genome-Wide Association Studies. 
Study1 Country Cases1,2 Controls1,2 ER+/ER- cases1,2  
Genotyping Platform 
ABCFS/kConFab Australia 282 285 88/72 (72) Illumina 610k 
BBCS4 U.K. 1609 1224 - Illumina 370k (cases)/ 
Illumina 1.2M (controls) 
DFBBCS5 Netherlands 464 3255 - Illumina 610k (cases) 
/Illumina 550k (controls) 
GC-HBOC6 Germany 634 477 - Affymetrix 5.0k(cases) 
/Affymetrix 6.0k 
(controls) 
GWAS_UK24 U.K. 3628 2663 361/160 (160) Illumina 670k 
(cases)/Illumina 1.2M 
(controls) 
HEBCS7 Finland 726 1012 522/229 (145) Illumina 550k+  610k 
(cases)/ Illumina 370k 
(controls) 
MARIE6 Germany 652 470 567/132 (76) Illumina 370k (cases) 
/Illumina  550k (controls) 
SASBAC Sweden 790 756 481/109 (109) Illumina 317k+240k 
(cases) /Illumina 550k 
(controls) 
 
1For further details see 3. 
2 Sample numbers after quality control exclusions.  
3Numbers in brackets are numbers of ER-cases after elimination of duplicates with TNBCC. 
4 Controls from Welcome Trust Case-Control Consortium. 
5 Controls from Rotterdam Study. 
6 Controls from KORA. 
7 Controls from NordicDB. 
  
Supplementary Table 1b Studies contributing to the BPC3 GWAS 
Study1 Country Cases Controls ER+/ER- cases2  
CPS-II USA 293 295 0/293 
EPIC Europe 511 500 0/511 
MEC USA 86 101 0/86 
NHS2 USA 76 374 0/76 
PBCS Poland 543 511 0/543 
PLCO USA 255 340 0/255 
NHS USA 234 184 0/234 
 
1 For further details see 4,5. 
2 Cases selected to be ER-negative 
Supplementary table 1c: Studies contributing to the Early-onset Breast Cancer GWAS (EBCG). 
Site1 Country Cases Controls ER+/ER- cases 
BCFR (AUS) Australia 593 250 368/176 
BCFR (NCA) USA 204 156 130/48 
BCFR (Ontario) Canada 668 395 404/185 
GESBC Germany 553 1,071 288/179 
LI US 225 275 112/53 
Seattle US 297 328 219/72 
USC US 983 - 662/198 
CCFR US - 227 - 
 
1 For further details see 6. 
 
  
Supplementary Table 1d: Studies contributing to the TNBCC GWAS 
 
 
1 For further details see 4,7,8. 
2 TNBCC used external controls, drawn from population-based studies from the same countries as the cases. 
3 Cases were selected to be ER-negative, PR-negative and HER2-negative. 
  
Study1 Country Cases 
Controls2 
ER+/ER- cases3  
ABCTB Australia 144 0 0/144 
MCCS Australia 39 0 0/39 
QIMR Australia 0 650 - 
BBCC Germany 218 0 0/218 
GENICA Germany 59 0 0/59 
MARIE Germany 198 0 0/198 
KORA Germany 0 215 - 
DFCI USA 246 0 0/246 
FCCC USA 120 0 0/120 
MCBCS USA 147 0 0/147 
CGEMS USA 0 947 - 
POSH UK 266 0 0/266 
SBCS UK 42 0 0/42 
WTCCC UK 0 1368 - 
Supplementary  Table 1e: Studies contributing to the iCOGS analysis. 
Study1 Country Cases Controls ER+/ER- Cases 
ABCFS Australia 643 551 383/204 
ABCS Netherlands 2029 1815 768/282 
BBCC Germany 548 458 460/67 
BBCS U.K. 1507 1397 493/108 
BIGGS Ireland 836 719 495/154 
BSUCH Germany 848 954 548/157 
CECILE France 1019 999 797/144 
CGPS Denmark 2948 4534 1919/357 
CNIO-BCS Spain 902 876 242/88 
CTS U.S.A. 68 71 0/68 
DEMOKRITOS Greece 413 95 0/413 
ESTHER Germany 478 502 304/98 
GENICA Germany 449 427 327/104 
HEBCS Finland 1658 1233 1292/235 
HMBCS Belarus 690 130 37/8 
KARBAC Sweden 722 662 338/63 
KBCP Finland 441 250 300/97 
kConFab/AOCS Australia 575 897 152/55 
LMBC Belgium 2671 1388 2071/378 
MARIE Germany 1743 1788 1328/346 
MBCSG Italy 488 400 149/42 
MCBCS U.S.A. 1836 1931 1486/269 
MCCS Australia 604 511 351/110 
MEC U.S.A. 731 741 415/87 
MTLGEBCS Canada 489 436 421/64 
NBCS Norway 908 217 620/201 
NBHS_TN U.S.A. 125 118 0/125 
OBCS Finland 505 414 405/100 
OFBCR Canada 1175 511 629/269 
ORIGO Netherlands 354 327 208/70 
OSU U.S.A. 207 203 0/207 
PBCS Poland 519 424 519/0 
pKARMA Sweden 5429 5568 3670/701 
RBCS Netherlands 599 699 323/124 
RPCI U.S.A 136 126 0/136 
SASBAC Sweden  397 661 198/43 
SBCS U.K. 832 848 376/98 
SEARCH U.K. 9293 8068 5146/1173 
SKK Germany 135 168 0/135 
SZBCS Poland 365 315 165/60 
UKBGS U.K. 470 470 95/22 
 
1 For further details see 3.
Supplementary Table 2: Number (proportion) of variants reaching imputation r2 (calculated by the info score IMPUTE2) in iCOGS and UK2 GWAS. 
 
Study #samples MAF #variants 
(proportion) 
r
2
>0.3 r
2
>0.5 r
2
>0.8 r
2
>0.9 
iCOGS 91,197 All 17,434,450 (1.00) 15,703,697 (0.90) 10,325,641 (0.59) 4,784,120 (0.27) 3,145,739 (0.18) 
  >=0.05 6,761,363 (1.00) 6,693,225 (0.99) 5,950,307 (0.88) 3,614,230 (0.53) 2,527,392 (0.37) 
  <0.05 10,673,087 (1.00) 9,010,472 (0.84) 4,375,334 (0.41) 1,169,890 (0.11) 618,347 (0.06) 
UK2 7,209 All 17,434,450 (1.00) 15,645,874 (0.90) 13,246,754 (0.76) 9,205,844 (0.53) 7,739,369 (0.45) 
  >=0.05 6,761,363 (1.00) 6,745,439 (0.998) 6,673,659 (0.987) 6,197,337 (0.92) 5,741,475 (0.85) 
  <0.05 10,673,087 (1.00) 8,900,435 (0.85)  6,573,095 (0.62) 3,008,507 (0.28) 1,997,894 (0.19) 
 
 
 
 
  
Supplementary Table 3. Association results for 79 breast cancer susceptibility loci previously reported in studies of women of European ancestry. 
Supplementary table 3a. Association results for overall breast cancer.   
 
SNP1 Chr2 Position3 Alleles4  MAF5 
GWAS 
GWAS OR 
(95%CI)6 
GWAS P7 MAF5 
iCOGS 
r2  
iCOGS8 
iCOGS OR 
(95%CI)6 
iCOGS P7 Combined P9 
rs616488 1 10566215 A/G 0.34 0.94(0.91-0.98) 0.00113 0.33 1 0.94(0.92-0.96) 8.75x10-09 3.82x10-11 
rs11552449 1 114448389 C/T 0.17 1.08(1.03-1.13) 0.00115 0.16 1 1.07(1.04-1.09) 5.98x10-07 2.75x10-09 
rs11249433 1 121280613 A/G 0.42 1.11(1.07-1.16) 6.71x10-09 0.4 1 1.09(1.07-1.12) 4.43x10-20 2.66x10-27 
rs6678914 1 202187176 G/A 0.42 0.94(0.91-0.98) 0.000942 0.41 1 1.00(0.98-1.02) 0.712 0.050 
rs4245739 1 204518842 A/C 0.27 1.03(0.99-1.07) 0.193 0.26 1 1.03(1.01-1.05) 0.00503 0.00206 
rs12710696 2 19320803 C/T 0.36 1.07(1.04-1.11) 4.57x10-05 0.36 1 1.04(1.02-1.06) 0.000481 4.36x10-07 
rs4849887 2 121245122 C/T 0.1 0.91(0.86-0.96) 0.00107 0.1 1 0.91(0.88-0.94) 4.89x10-09 2.04x10-11 
rs2016394 2 172972971 G/A 0.47 0.99(0.96-1.02) 0.512 0.48 1 0.95(0.94-0.97) 1.90x10-06 8.11x10-06 
rs1550623* 2 174212894 A/G 0.16 0.94(0.9-0.99) 0.0146 0.16 1 0.95(0.92-0.97) 2.88x10-05 1.27x10-06 
rs1045485* 2 202149589 G/C 0.13 0.91(0.87-0.96) 0.000612 0.13 1 0.97(0.94-1) 0.0463 0.000689 
rs13387042 2 217905832 A/G 0.49 0.87(0.84-0.9) 1.27x10-16 0.49 1 0.88(0.86-0.9) 8.91x10-41 1.15x10-55 
rs16857609 2 218296508 C/T 0.26 1.08(1.04-1.12) 3.08x10-05 0.26 1 1.08(1.06-1.11) 9.48x10-1 1.41x10-17 
rs6762644 3 4742276 A/G 0.39 1.04(1.01-1.08) 0.02 0.4 1 1.07(1.05-1.09) 6.28x10-11 8.58x10-12 
rs4973768 3 27416013 C/T 0.47 1.11(1.07-1.15) 7.45x10-10 0.47 1 1.1(1.08-1.12) 4.65x10-22 2.68x10-30 
rs12493607 3 30682939 G/C 0.35 1.04(1-1.07) 0.0385 0.34 1 1.06(1.04-1.08) 7.00x10-08 1.13x10-08 
rs1053338 3 63967900 A/G 0.13 1.06(1.01-1.12) 0.016 0.13 1 1.08(1.05-1.11) 1.65x10-07 9.08x10-9 
rs9790517 4 106084778 C/T 0.22 1.09(1.05-1.14) 1.38x10-05 0.22 1 1.05(1.03-1.08) 6.85x10-06 1.43x10-09 
rs6828523 4 175846426 C/A 0.12 0.9(0.85-0.95) 9.02x10-05 0.12 1 0.9(0.87-0.93) 2.77x10-12 1.14Ex10-15 
rs10069690 5 1279790 C/T 0.26 1.04(0.98-1.1) 0.219 0.26 1 1.06(1.04-1.09) 1.70x10-08 1.10x10-08 
rs7726159* 5 1282319 C/A 0.35 1(0.95-1.05) 0.956 0.34 1 1.04(1.02-1.06) 3.65x10-05 0.000174 
rs2736108 5 1297488 C/T 0.27 0.94(0.89-0.99) 0.0137 0.29 1 0.94(0.92-0.96) 5.47x10-08 2.44x10-09 
rs10941679 5 44706498 A/G 0.25 1.13(1.08-1.18) 2.31x10-07 0.25 1 1.12(1.1-1.15) 3.20x10-26 4.50x10-32 
rs889312 5 56031884 A/C 0.28 1.15(1.11-1.2) 2.26x10-14 0.28 1 1.12(1.1-1.15) 2.87x10-27 1.19x10-39 
rs10472076 5 58184061 T/C 0.36 1.06(1.02-1.09) 0.00275 0.38 1 1.05(1.03-1.07) 1.82x10-06 1.84x10-08 
rs1353747 5 58337481 T/G 0.1 0.92(0.87-0.98) 0.00698 0.1 1 0.92(0.89-0.95) 1.38x10-06 3.19x10-08 
rs1432679 5 158244083 T/C 0.43 1.08(1.04-1.11) 2.20x10-05 0.43 1 1.07(1.05-1.09) 3.60x10-12 3.93x10-16 
rs11242675* 6 1318878 T/C 0.38 0.95(0.92-0.98) 0.00362 0.38 1 0.96(0.94-0.98) 1.07x10-05 1.40x10-07 
rs204247 6 13722523 A/G 0.44 1.06(1.03-1.1) 0.000326 0.44 1 1.05(1.03-1.07) 2.71Ex10-07 4.18x10-10 
rs17529111 6 82128386 T/C 0.21 1.1(1.05-1.15) 3.50x10-05 0.22 1 1.06(1.04-1.08) 4.90x10-07 2.03x10-10 
rs12662670 6 151918856 T/G 0.08 1.22(1.14-1.29) 6.22x10-10 0.07 1 1.17(1.13-1.22) 1.03x10-18 6.80x10-27 
rs2046210 6 151948366 G/A 0.35 1.13(1.09-1.17) 3.61x10-12 0.34 1 1.08(1.06-1.1) 2.13x10-14 5.94x10-24 
rs6964587* 7 91630620 G/T 0.39 1.03(0.99-1.06) 0.11 0.39 1 1.05(1.03-1.07) 1.26x10-06 4.90x10-07 
rs720475 7 144074929 G/A 0.24 0.95(0.91-0.99) 0.00834 0.25 1 0.94(0.92-0.96) 1.23x10-08 3.85x10-10 
rs9693444 8 29509616 C/A 0.32 1.06(1.02-1.1) 0.00209 0.32 1 1.07(1.05-1.09) 1.09x10-10 1.00x10-12 
rs6472903 8 76230301 T/G 0.17 0.91(0.87-0.96) 9.46x10-05 0.18 1 0.91(0.89-0.93) 2.74x10-13 1.21x10-16 
rs2943559 8 76417937 A/G 0.07 1.19(1.11-1.27) 1.36x10-07 0.07 1 1.13(1.09-1.17) 6.81x10-11 1.41x10-16 
rs13281615 8 128355618 A/G 0.41 1.12(1.08-1.15) 1.91x10-10 0.4 1 1.1(1.08-1.12) 3.26x10-22 5.52x10-31 
rs11780156 8 129194641 C/T 0.17 1.08(1.03-1.13) 0.000763 0.16 1 1.07(1.04-1.09) 7.67x10-07 2.42x10-09 
rs1011970 9 22062134 G/T 0.17 1.11(1.06-1.16) 6.57x10-06 0.17 1 1.06(1.03-1.08) 2.68x10-05 4.02x10-09 
rs10759243 9 110306115 C/A 0.27 1.08(1.03-1.12) 0.000708 0.29 1 1.05(1.03-1.08) 6.92x10-07 2.69x10-09 
rs865686 9 110888478 T/G 0.37 0.91(0.88-0.94) 1.96x10-08 0.38 1 0.9(0.88-0.92) 4.49x10-27 6.42x10-34 
rs2380205* 10 5886734 C/T 0.44 0.95(0.92-0.98) 0.00147 0.44 1 0.99(0.97-1.01) 0.197 0.00699 
rs7072776 10 22032942 G/A 0.28 1.09(1.05-1.14) 1.79x10-06 0.29 1 1.07(1.05-1.09) 7.66x10-10 1.29x10-14 
rs11814448 10 22315843 A/C 0.02 1.35(1.17-1.56) 3.83x10-05 0.02 1 1.27(1.19-1.36) 2.73x10-13 6.47x10-17 
rs10995190 10 64278682 G/A 0.15 0.86(0.82-0.91) 1.30x10-09 0.16 1 0.86(0.83-0.88) 1.60x10-29 1.50x10-37 
rs704010 10 80841148 C/T 0.39 1.11(1.08-1.15) 6.32x10-10 0.38 1 1.08(1.06-1.1) 2.94x10-15 3.15x10-23 
rs7904519 10 114773927 A/G 0.45 1.09(1.05-1.12) 1.20x10-06 0.46 1 1.05(1.03-1.07) 4.74x10-08 9.21x10-13 
rs11199914 10 123093901 C/T 0.32 0.94(0.91-0.97) 0.000822 0.32 1 0.95(0.93-0.97) 2.25x10-06 8.20x10-09 
rs2981579 10 123337335 G/A 0.42 1.25(1.21-1.29) 2.21x10-37 0.4 1 1.27(1.24-1.29) 1.29x10-128 5.89x10-164 
rs3817198 11 1909006 T/C 0.32 1.07(1.03-1.11) 0.000454 0.31 1 1.07(1.05-1.09) 1.09x10-10 2.09x10-13 
rs3903072 11 65583066 G/T 0.47 0.93(0.9-0.97) 5.50x10-05 0.47 1 0.95(0.93-0.97) 3.02x10-07 1.14x10-10 
rs78540526 11 69331418 C/T 0.08 1.42(1.33-1.51) 2.30x10-26 0.08 0.99 1.34(1.29-1.38) 1.65x10-62 1.65x10-86 
rs554219 11 69331642 C/G 0.13 1.28(1.22-1.34) 2.66x10-23 0.12 1 1.26(1.23-1.3) 6.25x10-60 2.03x10-81 
rs75915166 11 69379161 C/A 0.06 1.36(1.27-1.47) 3.04x10-16 0.06 1 1.31(1.26-1.36) 2.40x10-43 1.00x10-57 
rs11820646 11 129461171 C/T 0.41 0.94(0.9-0.97) 0.00013 0.41 1 0.95(0.93-0.97) 1.72x10-07 1.22x10-10 
rs12422552* 12 14413931 G/C 0.26 1.08(1.04-1.12) 0.000104 0.26 1 1.04(1.02-1.07) 9.42x10-05 1.14x10-07 
rs10771399 12 28155080 A/G 0.11 0.8(0.75-0.84) 2.22x10-14 0.12 1 0.86(0.83-0.89) 2.05x10-22 4.76x10-34 
rs17356907 12 96027759 A/G 0.3 0.92(0.89-0.96) 2.34x10-05 0.3 1 0.91(0.9-0.93) 5.62x10-17 7.02x10-21 
rs1292011 12 115836522 A/G 0.42 0.92(0.89-0.95) 2.62x10-06 0.42 1 0.92(0.9-0.94) 1.22x10-16 1.72x10-21 
rs11571833* 13 32972626 A/T 0.01 1.22(0.96-1.54) 0.0999 0.01 1 1.27(1.15-1.4) 2.16x10-06 5.57x10-07 
rs2236007 14 37132769 G/A 0.2 0.93(0.89-0.97) 0.000452 0.21 1 0.93(0.91-0.95) 4.74x10-10 8.84x10-13 
rs2588809 14 68660428 C/T 0.15 1.02(0.97-1.07) 0.395 0.16 1 1.08(1.05-1.11) 3.72x10-09 2.28x10-08 
rs999737 14 69034682 C/T 0.23 0.88(0.84-0.91) 1.06x10-10 0.23 1 0.92(0.9-0.94) 4.10x10-13 1.98x10-21 
rs941764 14 91841069 A/G 0.33 1.04(1-1.08) 0.0482 0.34 1 1.07(1.05-1.09) 2.37x10-10 6.22x10-11 
rs3803662 16 52586341 G/A 0.28 1.25(1.2-1.29) 1.08x10-32 0.26 1 1.24(1.21-1.26) 2.71x10-86 4.15x10-117 
rs17817449 16 53813367 T/G 0.4 0.95(0.92-0.99) 0.00517 0.4 1 0.93(0.91-0.95) 6.90x10-13 2.47x10-14 
rs11075995 16 53855291 T/A 0.23 1.08(1.04-1.12) 0.000218 0.24 1 1.04(1.02-1.06) 0.000496 1.36x10-06 
rs13329835 16 80650805 A/G 0.22 1.11(1.06-1.15) 4.41x10-07 0.22 1 1.08(1.06-1.11) 6.08x10-12 2.36x10-17 
rs6504950 17 53056471 G/A 0.28 0.93(0.9-0.96) 0.00012 0.28 1 0.94(0.92-0.96) 8.15x10-09 4.76x10-12 
rs527616 18 24337424 G/C 0.37 0.9(0.86-0.93) 4.27x10-08 0.38 1 0.95(0.93-0.97) 1.47x10-07 7.50x10-13 
rs1436904 18 24570667 T/G 0.41 0.95(0.92-0.98) 0.00174 0.4 1 0.96(0.94-0.97) 4.73x10-06 3.23x10-08 
rs8170 19 17389704 G/A 0.19 1.09(1.05-1.14) 7.75x10-05 0.19 1 1.04(1.02-1.07) 0.000997 1.66x10-06 
rs2363956 19 17394124 G/T 0.49 1.08(1.04-1.12) 9.58x10-06 0.49 1 1.03(1.01-1.05) 0.00368 2.49x10-06 
rs4808801 19 18571141 A/G 0.34 0.95(0.92-0.99) 0.00764 0.35 1 0.93(0.91-0.94) 5.89x10-14 4.12x10-15 
rs3760982 19 44286513 G/A 0.47 1.04(1.01-1.07) 0.0218 0.46 1 1.05(1.03-1.07) 9.64x10-08 8.00x10-09 
rs2823093 21 16520832 G/A 0.26 0.95(0.92-0.99) 0.0154 0.27 1 0.93(0.91-0.95) 2.39x10-12 3.18x10-13 
rs1787996110 22 29121087 A/G 0.03 0.93(0.7-1.23) 0.593 0.0049 1 1.37(1.21-1.55) 7.85x10-07 1.67x10-5 
rs132390 22 29621477 T/C 0.03 1.2(1.07-1.34) 0.00163 0.04 1 1.14(1.08-1.2) 3.79x10-07 3.22x10-09 
rs6001930 22 40876234 T/C 0.1 1.17(1.1-1.23) 4.00x10-08 0.11 1 1.12(1.09-1.16) 3.53x10-14 1.71x10-20 
 
  
1SNPs marked in bold and asterisked do not reach P<5x10-8 for overall, ER-positive or ER-negative breast cancer. 
2Chromosome. 
3Build 37 position. 
4Reference/effect allele (forward strand). 
5Mean frequency of the effect allele. 
6Per-allele OR for the effect allele. 
71 degree of freedom trend test. 
8Mean imputation r2 from IMPUTE2 (r2=1 for genotyped SNPs). 
9Combined P-value based on meta-analysis of the GWAS and iCOGS results. 
10rs17879961 was not included in the main analysis as MAF <0.005 in iCOGS. 
 Variants that do not reach P<5x10-8 in overall, ER-negative or ER-positive disease 
Supplementary Table 3b: Association results for ER-positive breast cancer.   
 
SNP1 Chr2 Position3 Alleles4  MAF 
GWAS5 
OR GWAS 
(95%CI)6 
GWAS P7 MAF 
iCOGS5 
r2 
iCOGS8 
OR iCOGS 
(95% CI)6 
iCOGS P7 Combined P9 
rs616488 1 10566215 A/G 0.32 0.98(0.9-1.07) 0.661 0.33 1 0.96(0.94-0.98) 0.00106 0.00107 
rs11552449 1 114448389 C/T 0.17 1.12(1-1.24) 0.0423 0.16 1 1.08(1.05-1.11) 3.06x10-07 4.30x10-08 
rs11249433 1 121280613 A/G 0.39 1.11(1.03-1.21) 0.00988 0.4 1 1.12(1.09-1.14) 5.37x10-22 1.87x10-23 
rs6678914 1 202187176 G/A 0.43 1.01(0.93-1.1) 0.754 0.41 1 1.01(0.99-1.04) 0.308 0.286 
rs4245739 1 204518842 A/C 0.24 0.94(0.85-1.03) 0.195 0.26 1 1(0.98-1.03) 0.878 0.847 
rs12710696 2 19320803 C/T 0.35 1.06(0.98-1.15) 0.159 0.36 1 1.01(0.98-1.03) 0.531 0.325 
rs4849887 2 121245122 C/T 0.09 0.89(0.77-1.02) 0.102 0.1 1 0.91(0.88-0.95) 1.73x10-06 4.51x10-07 
rs2016394 2 172972971 G/A 0.48 0.94(0.86-1.01) 0.1 0.48 1 0.94(0.92-0.96) 1.98x10-08 4.93x10-09 
rs1550623* 2 174212894 A/G 0.16 0.88(0.79-0.99) 0.0289 0.16 1 0.95(0.92-0.98) 0.000877 0.000148 
rs1045485* 2 202149589 G/C 0.13 0.92(0.82-1.04) 0.205 0.13 1 0.98(0.94-1.01) 0.181 0.103 
rs13387042 2 217905832 A/G 0.49 0.82(0.75-0.88) 5.46x10-07 0.49 1 0.86(0.84-0.88) 2.26x10-37 1.90x10-42 
rs16857609 2 218296508 C/T 0.28 1.02(0.93-1.11) 0.693 0.26 1 1.09(1.06-1.11) 2.35x10-10 5.46x10-10 
rs6762644 3 4742276 A/G 0.39 1.13(1.05-1.23) 0.00226 0.4 1 1.07(1.05-1.09) 8.05x10-09 1.74x10-10 
rs4973768 3 27416013 C/T 0.46 1.15(1.06-1.25) 0.000491 0.47 1 1.1(1.08-1.13) 1.05x10-17 3.91x10-20 
rs12493607 3 30682939 G/C 0.35 1.05(0.96-1.14) 0.261 0.34 1 1.07(1.04-1.09) 5.67x10-08 3.18x10-08 
rs1053338 3 63967900 A/G 0.12 1.09(0.96-1.23) 0.18 0.13 1 1.04(1.08-1.11) 2.86x10-06 1.11x10-06 
rs9790517 4 106084778 C/T 0.23 1.08(0.98-1.18) 0.139 0.22 1 1.06(1.03-1.09) 1.54x10-05 5.07x10-06 
rs6828523 4 175846426 C/A 0.12 0.86(0.76-0.98) 0.0191 0.12 1 0.87(0.84-0.9) 1.54x10-14 9.56x10-16 
rs10069690 5 1279790 C/T 0.27 1(0.9-1.11) 0.946 0.26 1 1.04(1.01-1.06) 0.00778 0.0101 
rs7726159* 5 1282319 C/A 0.35 0.98(0.89-1.08) 0.709 0.34 1 1.03(1.01-1.06) 0.00676 0.0112 
rs2736108 5 1297488 C/T 0.26 0.98(0.88-1.09) 0.724 0.29 1 0.96(0.94-0.99) 0.00239 0.00239 
rs10941679 5 44706498 A/G 0.25 1.19(1.09-1.31) 0.000236 0.25 1 1.15(1.12-1.18) 2.84x10-28 4.00x10-31 
rs889312 5 56031884 A/C 0.28 1.07(0.98-1.17) 0.124 0.28 1 1.14(1.12-1.17) 1.39x10-26 1.07x10-26 
rs10472076 5 58184061 T/C 0.37 1.1(1.01-1.19) 0.027 0.38 1 1.04(1.01-1.06) 0.00191 0.000339 
rs1353747 5 58337481 T/G 0.09 0.95(0.82-1.09) 0.442 0.1 1 0.93(0.89-0.97) 0.00025 0.000187 
rs1432679 5 158244083 T/C 0.44 1.07(0.99-1.16) 0.102 0.43 1 1.07(1.04-1.09) 8.23x10-09 2.08x10-09 
rs11242675* 6 1318878 T/C 0.4 0.97(0.89-1.05) 0.455 0.38 1 0.96(0.94-0.98) 0.000754 0.000572 
rs204247 6 13722523 A/G 0.44 1.03(0.95-1.12) 0.501 0.44 1 1.07(1.04-1.09) 3.55x10-08 3.98x10-08 
rs17529111 6 82128386 T/C 0.23 1.13(1.03-1.24) 0.0124 0.22 1 1.06(1.03-1.09) 3.61x10-05 3.22x10-06 
rs12662670 6 151918856 T/G 0.07 1.12(0.96-1.32) 0.157 0.07 1 1.13(1.08-1.18) 2.05x10-08 7.33x10-09 
rs2046210 6 151948366 G/A 0.31 1.1(1.01-1.19) 0.0342 0.34 1 1.06(1.03-1.08) 1.00x10-05 1.42x10-06 
rs6964587* 7 91630620 G/T 0.39 1.03(0.94-1.11) 0.55 0.39 1 1.06(1.04-1.08) 5.78x10-07 6.46x10-07 
rs720475 7 144074929 G/A 0.25 0.99(0.9-1.09) 0.852 0.25 1 0.93(0.91-0.96) 1.03x10-07 2.34x10-07 
rs9693444 8 29509616 C/A 0.33 1.05(0.96-1.14) 0.264 0.32 1 1.07(1.05-1.1) 1.28x10-08 7.49x10-09 
rs6472903 8 76230301 T/G 0.18 0.89(0.8-0.99) 0.0254 0.18 1 0.91(0.88-0.94) 1.14x10-09 1.00x10-10 
rs2943559 8 76417937 A/G 0.07 1.06(0.9-1.24) 0.517 0.07 1 1.13(1.09-1.18) 4.64x10-09 5.38x10-09 
rs13281615 8 128355618 A/G 0.4 1.18(1.09-1.28) 7.04E-05 0.4 1 1.11(1.08-1.13) 5.45x10-18 5.73x10-21 
rs11780156 8 129194641 C/T 0.15 1.15(1.03-1.29) 0.012 0.16 1 1.07(1.04-1.11) 5.31x10-06 4.39x10-07 
rs1011970 9 22062134 G/T 0.18 1.08(0.97-1.2) 0.151 0.17 1 1.04(1.01-1.08) 0.00438 0.00173 
rs10759243 9 110306115 C/A 0.28 1.02(0.93-1.11) 0.707 0.29 1 1.08(1.05-1.11) 1.48x10-09 2.91x10-09 
rs865686 9 110888478 T/G 0.38 0.86(0.79-0.94) 0.000502 0.38 1 0.87(0.85-0.89) 2.14x10-30 4.93x10-33 
rs2380205* 10 5886734 C/T 0.45 0.91(0.84-0.99) 0.0273 0.44 1 0.98(0.96-1) 0.062 0.0167 
rs7072776 10 22032942 G/A 0.26 1.14(1.04-1.25) 0.00436 0.28 1 1.09(1.06-1.12) 1.17x10-11 2.96x10-13 
rs11814448 10 22315843 A/C 0.02 1.11(0.8-1.55) 0.53 0.02 1 1.27(1.18-1.37) 6.44E-10 7.08x10-10 
rs10995190 10 64278682 G/A 0.17 0.84(0.75-0.93) 0.00153 0.16 1 0.85(0.83-0.88) 9.68x10-23 6.37x10-25 
rs704010 10 80841148 C/T 0.37 1.07(0.98-1.16) 0.132 0.38 1 1.1(1.07-1.12) 2.09x10-15 8.34x10-16 
rs7904519 10 114773927 A/G 0.45 1.11(1.02-1.2) 0.0116 0.46 1 1.04(1.02-1.07) 0.000168 1.70x10-05 
rs11199914 10 123093901 C/T 0.34 0.93(0.85-1.01) 0.1 0.32 1 0.93(0.91-0.96) 5.50x10-08 1.38x10-08 
rs2981579 10 123337335 G/A 0.41 1.37(1.26-1.49) 5.12x10-14 0.4 1 1.33(1.3-1.36) 9.36x10-133 5.79x10-145 
rs3817198 11 1909006 T/C 0.3 1.01(0.92-1.1) 0.888 0.31 1 1.09(1.06-1.11) 1.55x10-11 6.16x10-11 
rs3903072 11 65583066 G/T 0.5 0.9(0.83-0.97) 0.00878 0.47 1 0.95(0.92-0.97) 1.11x10-06 6.87x10-08 
rs78540526 11 69331418 C/T 0.08 1.37(1.19-1.59) 1.87E-05 0.08 0.99 1.41(1.35-1.46) 2.31x10-66 2.50x10-70 
rs554219 11 69331642 C/G 0.13 1.35(1.2-1.51) 6.55E-07 0.12 1 1.32(1.28-1.37) 9.07x10-65 3.82x10-70 
rs75915166 11 69379161 C/A 0.06 1.23(1.03-1.46) 0.0204 0.06 1 1.38(1.32-1.44) 9.52x10-46 1.48x10-46 
rs11820646 11 129461171 C/T 0.43 0.92(0.85-1) 0.0514 0.41 1 0.95(0.93-0.97) 2.68x10-06 4.48x10-07 
rs12422552* 12 14413931 G/C 0.25 1.14(1.04-1.25) 0.00592 0.26 1 1.04(1.01-1.07) 0.00204 0.000217 
rs10771399 12 28155080 A/G 0.11 0.82(0.72-0.94) 0.00389 0.12 1 0.88(0.85-0.91) 5.77x10-13 1.23x10-14 
rs17356907 12 96027759 A/G 0.31 0.89(0.82-0.98) 0.0157 0.3 1 0.91(0.89-0.93) 1.47x10-14 7.99x10-16 
rs1292011 12 115836522 A/G 0.41 0.88(0.82-0.96) 0.00346 0.42 1 0.91(0.89-0.93) 8.75x10-17 1.36x10-18 
rs11571833* 13 32972626 A/T 0.01 1.64(1.03-2.62) 0.0374 0.01 1 1.26(1.12-1.41) 0.00013 2.47x10-05 
rs2236007 14 37132769 G/A 0.2 0.87(0.78-0.96) 0.00649 0.21 1 0.91(0.89-0.94) 1.55x10-10 5.48x10-12 
rs2588809 14 68660428 C/T 0.16 1.04(0.93-1.16) 0.467 0.16 1 1.09(1.06-1.13) 4.89x10-09 5.39x10-09 
rs999737 14 69034682 C/T 0.23 0.86(0.78-0.94) 0.00153 0.23 1 0.91(0.89-0.94) 5.00x10-11 6.90x10-13 
rs941764 14 91841069 A/G 0.34 1.07(0.99-1.17) 0.104 0.34 1 1.07(1.05-1.1) 3.66x10-09 9.41x10-10 
rs3803662 16 52586341 G/A 0.28 1.28(1.17-1.39) 3.43E-08 0.26 1 1.26(1.23-1.29) 4.02x10-73 9.98x10-80 
rs17817449 16 53813367 T/G 0.4 0.98(0.9-1.06) 0.552 0.4 1 0.93(0.91-0.96) 5.77x10-09 8.03x10-09 
rs11075995 16 53855291 T/A 0.25 1.06(0.96-1.16) 0.235 0.24 1 1.03(1-1.05) 0.0473 0.0258 
rs13329835 16 80650805 A/G 0.23 1.09(0.99-1.2) 0.0716 0.22 1 1.09(1.06-1.12) 1.64x10-10 3.12x10-11 
rs6504950 17 53056471 G/A 0.27 0.95(0.87-1.04) 0.279 0.28 1 0.93(0.91-0.95) 2.94x10-08 1.79x10-08 
rs527616 18 24337424 G/C 0.41 0.9(0.82-0.98) 0.0118 0.38 1 0.95(0.93-0.98) 4.49x10-05 4.28x10-06 
rs1436904 18 24570667 T/G 0.39 0.94(0.87-1.03) 0.177 0.4 1 0.94(0.92-0.96) 1.44x10-07 5.65x10-08 
rs8170 19 17389704 G/A 0.2 0.95(0.85-1.05) 0.285 0.19 1 1.01(0.98-1.04) 0.597 0.825 
rs2363956 19 17394124 G/T 0.46 0.97(0.89-1.05) 0.396 0.49 1 1(0.98-1.02) 0.946 0.767 
rs4808801 19 18571141 A/G 0.35 0.95(0.87-1.03) 0.238 0.35 1 0.93(0.91-0.95) 3.82x10-10 2.18x10-10 
rs3760982 19 44286513 G/A 0.45 1.07(0.99-1.16) 0.102 0.46 1 1.06(1.04-1.08) 5.08x10-07 1.30x10-07 
rs2823093 21 16520832 G/A 0.27 0.97(0.87-1.07) 0.546 0.27 1 0.91(0.89-0.94) 3.18x10-12 4.81x10-12 
rs17879961 22 29121087 A/G 0.04 0.89(0.57-1.36) 0.582 0.0049 1 1.51(1.31-1.73) 3.49x10-09 2.81x10-08 
rs132390 22 29621477 T/C 0.04 1.17(0.93-1.48) 0.177 0.04 1 1.14(1.08-1.21) 8.44x10-06 3.35x10-06 
rs6001930 22 40876234 T/C 0.12 1.08(0.95-1.22) 0.24 0.11 1 1.12(1.08-1.16) 2.81x10-10 1.64x10-10 
 
1SNPs marked in bold and asterisked do not reach P<5x10-8 for overall, ER-positive or ER-negative breast cancer. 
2Chromosome. 
3Build 37 position. 
4Reference/effect allele, based on the overall frequency in controls in iCOGS (forward strand). 
5Mean frequency of the effect allele. 
6Per-allele OR for the effect allele. 
71 degree of freedom trend test. 
8Mean imputation r2 from IMPUTE2 (r2=1 for genotyped SNPs). 
9Combined P-value based on meta-analysis of the GWAS and iCOGS results. 
10rs17879961 was not included in the main analysis as MAF <0.005 in iCOGS. 
 Variants that do not reach P<5x10-8 in overall, ER-negative or ER-positive disease 
 
  
Supplementary Table 3c. Association results for ER-negative breast cancer.    
 
SNP1 Chr2 Position3 Alleles4  MAF 
GWAS5 
OR GWAS 
(95%CI)6 
GWAS P7 MAF 
iCOGS5 
r2 iCOGS8 OR iCOGS 
(95%CI)6  
iCOGS P7 Combine P9 
rs616488 1 10566215 A/G 0.33 0.92(0.87-0.97) 0.0033 0.33 1 0.91(0.87-0.95) 3.91E-06 2.99x10-08 
rs11552449 1 114448389 C/T 0.17 1.09(1.02-1.17) 0.0159 0.16 1 1.04(0.99-1.1) 0.0833 0.00689 
rs11249433 1 121280613 A/G 0.42 1.06(1-1.13) 0.066 0.4 1 1(0.96-1.04) 0.938 0.334 
rs6678914 1 202187176 G/A 0.41 0.88(0.83-0.93) 2.32x10-06 0.41 1 0.92(0.88-0.96) 1.69E-05 3.83x10-10 
rs4245739 1 204518842 A/C 0.28 1.12(1.05-1.18) 0.000218 0.26 1 1.15(1.11-1.2) 1.75E-11 1.23x10-14 
rs12710696 2 19320803 C/T 0.37 1.07(1.02-1.13) 0.00955 0.36 1 1.1(1.06-1.14) 1.24E-06 3.95x10-08 
rs4849887 2 121245122 C/T 0.1 0.96(0.88-1.05) 0.345 0.1 1 0.9(0.85-0.96) 0.00223 0.00233 
rs2016394 2 172972971 G/A 0.47 1.07(1.01-1.12) 0.013 0.48 1 1(0.96-1.03) 0.817 0.161 
rs1550623* 2 174212894 A/G 0.16 0.98(0.91-1.05) 0.572 0.16 1 0.95(0.91-1.01) 0.0784 0.0651 
rs1045485* 2 202149589 G/C 0.13 0.9(0.83-0.97) 0.00887 0.13 1 0.98(0.92-1.03) 0.43 0.0198 
rs13387042 2 217905832 A/G 0.48 0.94(0.9-0.99) 0.0263 0.49 1 0.96(0.93-1) 0.0345 0.00158 
rs16857609 2 218296508 C/T 0.26 1.06(1-1.13) 0.0466 0.26 1 1.09(1.04-1.13) 0.000101 3.06x10-05 
rs6762644 3 4742276 A/G 0.39 0.98(0.93-1.04) 0.502 0.4 1 1.02(0.98-1.06) 0.276 0.719 
rs4973768 3 27416013 C/T 0.48 1.03(0.97-1.08) 0.326 0.47 1 1.05(1.01-1.09) 0.00897 0.00662 
rs12493607 3 30682939 G/C 0.35 0.99(0.94-1.05) 0.823 0.34 1 1.02(0.98-1.06) 0.373 0.527 
rs1053338 3 63967900 A/G 0.12 1.02(0.94-1.10) 0.63 0.13 1 1.06(1.00-1.12) 0.04 0.05 
rs9790517 4 106084778 C/T 0.23 1.1(1.03-1.17) 0.00306 0.22 1 1.03(0.98-1.07) 0.275 0.00896 
rs6828523 4 175846426 C/A 0.12 0.94(0.86-1.02) 0.136 0.12 1 1.02(0.96-1.08) 0.484 0.772 
rs10069690 5 1279790 C/T 0.29 1.07(0.95-1.21) 0.261 0.26 1 1.16(1.12-1.21) 3.97x10-13 5.84x10-13 
rs7726159* 5 1282319 C/A 0.35 1.07(0.98-1.16) 0.129 0.34 1 1.09(1.05-1.14) 9.75x10-06 2.19x10-06 
rs2736108 5 1297488 C/T 0.26 0.93(0.84-1.03) 0.168 0.29 1 0.89(0.85-0.93) 5.13x10-08 1.41x10-08 
rs10941679 5 44706498 A/G 0.24 1.07(0.98-1.16) 0.129 0.25 1 1.03(0.99-1.08) 0.147 0.0352 
rs889312 5 56031884 A/C 0.28 1.07(1.01-1.14) 0.0142 0.28 1 1.06(1.02-1.1) 0.00663 0.000239 
rs10472076 5 58184061 T/C 0.36 1.04(0.99-1.1) 0.134 0.38 1 1.06(1.02-1.1) 0.00464 0.0023 
rs1353747 5 58337481 T/G 0.09 0.97(0.89-1.06) 0.512 0.1 1 0.92(0.86-0.98) 0.00835 0.0098 
rs1432679 5 158244083 T/C 0.43 1.06(1-1.11) 0.039 0.43 1 1.08(1.04-1.13) 2.39x10-05 2.83x10-06 
rs11242675* 6 1318878 T/C 0.37 0.94(0.89-0.99) 0.015 0.38 1 0.96(0.92-0.99) 0.0217 0.00069 
rs204247 6 13722523 A/G 0.44 1.08(1.03-1.14) 0.00307 0.44 1 1.01(0.97-1.04) 0.739 0.0489 
rs17529111 6 82128386 T/C 0.22 1.17(1.08-1.26) 0.000167 0.22 1 1.05(1-1.09) 0.0467 0.000356 
rs12662670 6 151918856 T/G 0.08 1.25(1.13-1.37) 7.53x10-06 0.07 1 1.24(1.16-1.32) 3.00x10-10 8.90x10-15 
rs2046210 6 151948366 G/A 0.35 1.15(1.09-1.22) 2.26x10-07 0.34 1 1.16(1.12-1.21) 8.88x10-14 4.10x10-20 
rs6964587* 7 91630620 G/T 0.39 1.01(0.96-1.06) 0.79 0.39 1 1.04(1-1.08) 0.06 0.09 
rs720475 7 144074929 G/A 0.24 1.03(0.96-1.09) 0.415 0.26 1 0.99(0.95-1.03) 0.694 0.968 
rs9693444 8 29509616 C/A 0.32 1.02(0.96-1.07) 0.567 0.32 1 1.09(1.04-1.13) 4.66E-05 0.000342 
rs6472903 8 76230301 T/G 0.18 0.97(0.9-1.04) 0.325 0.18 1 0.94(0.89-0.99) 0.0126 0.00892 
rs2943559 8 76417937 A/G 0.07 1.16(1.05-1.29) 0.00384 0.07 1 1.07(1-1.15) 0.0552 0.00133 
rs13281615 8 128355618 A/G 0.42 1.07(1.01-1.12) 0.0157 0.4 1 1.03(0.99-1.07) 0.195 0.0129 
rs11780156 8 129194641 C/T 0.18 1.02(0.95-1.09) 0.586 0.16 1 1.06(1-1.11) 0.032 0.0365 
rs1011970 9 22062134 G/T 0.17 1.08(1.01-1.15) 0.0335 0.17 1 1.11(1.06-1.17) 1.42x10-05 7.36x10-07 
rs10759243 9 110306115 C/A 0.27 1.1(1.02-1.18) 0.0168 0.29 1 1.01(0.97-1.05) 0.608 0.15 
rs865686 9 110888478 T/G 0.36 0.97(0.92-1.03) 0.332 0.38 1 0.99(0.95-1.03) 0.487 0.211 
rs2380205* 10 5886734 C/T 0.44 0.98(0.93-1.03) 0.492 0.44 1 1.01(0.97-1.05) 0.718 0.755 
rs7072776 10 22032942 G/A 0.28 1.04(0.99-1.11) 0.136 0.29 1 0.94(0.91-0.98) 0.00709 0.216 
rs11814448 10 22315843 A/C 0.02 1.22(0.92-1.62) 0.164 0.02 1 1.2(1.06-1.37) 0.00399 0.00143 
rs10995190 10 64278682 G/A 0.15 0.92(0.85-0.98) 0.0173 0.16 1 0.87(0.83-0.92) 3.34x10-07 3.75x10-08 
rs704010 10 80841148 C/T 0.38 1.07(1.02-1.13) 0.0114 0.38 1 1.03(0.99-1.07) 0.0969 0.00388 
rs7904519 10 114773927 A/G 0.46 1.12(1.06-1.18) 3.28x10-05 0.46 1 1.04(1.01-1.08) 0.021 7.54x10-06 
rs11199914 10 123093901 C/T 0.32 0.96(0.91-1.02) 0.156 0.32 1 1.02(0.98-1.06) 0.398 0.971 
rs2981579 10 123337335 G/A 0.42 1.02(0.97-1.08) 0.367 0.4 1 1.02(0.99-1.06) 0.205 0.0906 
rs3817198 11 1909006 T/C 0.32 1.06(1-1.12) 0.0406 0.31 1 1.06(1.02-1.11) 0.0028 0.000401 
rs3903072 11 65583066 G/T 0.47 0.94(0.89-0.99) 0.015 0.47 1 0.97(0.94-1.01) 0.173 0.00625 
rs78540526 11 69331418 C/T 0.08 1.1(0.98-1.24) 0.108 0.08 0.99 1.03(0.96-1.11) 0.376 0.138 
rs554219 11 69331642 C/G 0.13 1.08(1-1.17) 0.0483 0.12 1 1.02(0.96-1.08) 0.486 0.1 
rs75915166 11 69379161 C/A 0.07 1.04(0.91-1.19) 0.591 0.06 1 1.06(0.98-1.14) 0.161 0.196 
rs11820646 11 129461171 C/T 0.4 0.93(0.88-0.98) 0.0092 0.41 1 0.96(0.92-1) 0.0295 0.000967 
rs12422552* 12 14413931 G/C 0.26 1.08(1.01-1.14) 0.0161 0.26 1 1.05(1-1.09) 0.0338 0.0023 
rs10771399 12 28155080 A/G 0.1 0.8(0.72-0.87) 1.46x10-06 0.12 1 0.84(0.79-0.9) 5.05x10-08 1.64x10-13 
rs17356907 12 96027759 A/G 0.3 0.89(0.84-0.94) 8.10x10-05 0.3 1 0.95(0.91-0.99) 0.0101 6.25x10-06 
rs1292011 12 115836522 A/G 0.42 0.98(0.93-1.03) 0.493 0.42 1 0.98(0.95-1.02) 0.416 0.286 
rs11571833* 13 32972626 A/T 0.01 1.35(0.86-2.11) 0.19 0.01 1 1.48(1.24-1.77) 1.57x10-05 1.01x10-05 
rs2236007 14 37132769 G/A 0.21 1(0.94-1.07) 0.938 0.21 1 0.96(0.92-1) 0.0777 0.118 
rs2588809 14 68660428 C/T 0.15 0.93(0.86-1.01) 0.0727 0.16 1 1.01(0.96-1.07) 0.609 0.532 
rs999737 14 69034682 C/T 0.23 0.92(0.86-0.98) 0.00631 0.23 1 0.94(0.9-0.98) 0.00728 0.00019 
rs941764 14 91841069 A/G 0.32 0.96(0.89-1.03) 0.228 0.34 1 1.04(1-1.08) 0.0448 0.316 
rs3803662 16 52586341 G/A 0.29 1.12(1.06-1.18) 0.000139 0.26 1 1.15(1.1-1.19) 6.51x10-11 5.11x10-14 
rs17817449 16 53813367 T/G 0.4 0.96(0.91-1.02) 0.167 0.4 1 0.91(0.87-0.94) 3.43x10-07 5.59x10-07 
rs11075995 16 53855291 T/A 0.23 1.12(1.05-1.19) 0.000517 0.24 1 1.1(1.05-1.15) 1.14x10-05 3.30x10-08 
rs13329835 16 80650805 A/G 0.23 1.04(0.98-1.1) 0.242 0.22 1 1.02(0.98-1.07) 0.4 0.161 
rs6504950 17 53056471 G/A 0.28 0.96(0.91-1.02) 0.206 0.28 1 0.98(0.94-1.02) 0.239 0.0824 
rs527616 18 24337424 G/C 0.38 0.94(0.88-1.01) 0.0723 0.38 1 0.98(0.94-1.02) 0.331 0.064 
rs1436904 18 24570667 T/G 0.4 0.98(0.93-1.03) 0.368 0.4 1 1(0.97-1.04) 0.816 0.689 
rs8170 19 17389704 G/A 0.19 1.17(1.09-1.25) 7.74E-06 0.19 1 1.14(1.09-1.2) 1.94x10-08 9.09x10-13 
rs2363956 19 17394124 G/T 0.49 1.13(1.07-1.19) 4.53E-06 0.49 1 1.13(1.09-1.17) 1.79x10-10 3.04x10-15 
rs4808801 19 18571141 A/G 0.34 0.99(0.94-1.05) 0.686 0.35 1 0.92(0.88-0.96) 2.76x10-05 0.000241 
rs3760982 19 44286513 G/A 0.47 1.03(0.98-1.09) 0.247 0.46 1 1.04(1-1.08) 0.0384 0.023 
rs2823093 21 16520832 G/A 0.26 1.02(0.96-1.08) 0.59 0.27 1 0.97(0.93-1.01) 0.13 0.417 
rs1787996110 22 29121087 A/G 0.03 1.07(0.72-1.59) 0.748 0.0049 1 1.01(0.78-1.31) 0.927 0.8 
rs132390 22 29621477 T/C 0.03 0.93(0.74-1.18) 0.562 0.04 1 1.1(1-1.21) 0.0511 0.156 
rs6001930 22 40876234 T/C 0.11 1.17(1.08-1.28) 0.000313 0.11 1 1.1(1.04-1.17) 0.000866 3.91x10-06 
 
1SNPs marked in bold and asterisked do not reach P<5x10-8 for overall, ER-positive or ER-negative breast cancer. 
2Chromosome. 
3Build 37 position. 
4Reference/effect allele, based on the overall frequency in controls in iCOGS (forward strand). 
5Mean frequency of the effect allele. 
6Per-allele OR for the effect allele. 
71 degree of freedom trend test. 
8Mean imputation r2 from IMPUTE2 (r2=1 for genotyped SNPs). 
9Combined P-value based on meta-analysis of the GWAS and iCOGS results. 
10rs17879961 was not included in the main analysis as MAF <0.005 in iCOGS. 
 Variants that do not reach P<5x10-8 in overall, ER-negative or ER-positive disease 
 
 
 
 
 
 
Supplementary Table 4. Loci associated with breast cancer at P<5x10-8 that failed to reach P<5x10-8 after reanalysis in which imputation was performed 
without pre-phasing (see Online Methods). 
 
variant Chromosome Position1 Alleles2 MAF3 Imputation r2 
iCOGS 
Original p-value Re-imputation 
r2 iCOGS 
p-value after 
re-imputation 
rs754536 2 25176200 T/C 0.48 0.68 4.23x10-9 0.60 2.87x10-7 
rs1881936954 8 11174465 C/T 0.01 0.51 2.65x10-8 0.23 0.15 
rs2229510 19 12903059 C/A 0.03 0.73 7.11x10-9 0.56 1.15x10-7 
 
1 build 37 position 
2 Reference/effect allele, based on the overall frequency in controls in iCOGS (forward strand). 
3 Mean frequency of the effect allele. 
4 this variant after re-imputation failed the imputation threshold for inclusion in the meta-analysis  
 
  
Supplementary  Table 5. Validation of 15 risk loci by direct genotyping in ~4,000 individuals from SEARCH.  
 
Best variant Chromosome Position1 Highly correlated 
SNP genotyped on 
iCOGS  
Reasons for selection on 
iCOGS 
Imputation2  
r2 iCOGS 
Correlation3 Estimate4 
imputed 
Estimate5 
genotyped 
rs12405132 1 145644984 -  0.96 0.99 -0.029 -0.026 
rs12048493 1 149927034 rs11205227 Published GWAS hit for 
height9 
 
- - - - 
rs72755295 1 242034263 rs4149909 Breast cancer combined 
GWAS, menopause 
association, candidate from 
OCAC 
- - - - 
rs6796502 3 46866866 -  0.91 0.95 -0.062 -0.068 
rs131626536 5 16187528 -  0.72 0.7 -0.066 -0.057 
rs2012709 5 32567732 -  0.81 0.84 0.109 0.114 
rs7707921 5 81538046 -  0.88 0.94 -0.135 -0.135 
rs92574087 6 28926220 -  0.92 - - - 
rs4593472 7 130667121 rs4593472 Breast cancer combined 
GWAS 
- - - - 
rs13365225 8 36858483 -  0.94 0.99 -0.064 -0.076 
rs13267382 8 117209548 -  0.97 0.96 0.140 0.141 
rs116270328 14 93104072 -  0.73 0.78 -0.055 -0.040 
chr17:29230520:D9 17 29230520 -  0.76 - - - 
rs745570 17 77781725 -  0.93 0.92 -0.068 -0.073 
rs6507583 18 42399590 -  0.96 0.98 -0.057 -0.056 
 
1 build 37 position 
2  Mean info score from IMPUTE2   
3 Correlation squared between the imputed and genotyped genotypes for 4123 samples in SEARCH 
4 Beta coefficient in the subset of SEARCH samples from the imputed data 
5 Beta coefficient in the subset of SEARCH samples from the genotyped data 
6 SNP rs186951, correlated with rs13162653, had better imputation quality and also reached P<5x10-8 (r2=0.91, P=2.1x10-8). 
7 genotyped rs28912458 as an alternative (correlation between genotyped and imputed is 0.997, p combined in meta-analysis 6.263e-08)  
8 SNP rs11621587, correlated with rs11627032, had better imputation quality and also reached P<5x10-8 (r2=0.94, P=2.8x10-8). 
9 Alternative SNP failed genotyping. SNP rs62070644,correlated with chr17:29230520:D, had better imputation quality and also reached P<5x10-8 (r2=0.98, 
P=4.5x10-8). 
  
Supplementary Table 6:  Genotype-specific OR estimates for 15 novel risk loci, and analysis of heterogeneity in the per-allele ORs among studies, based on 
iCOGS data.  
 
Top variant Chr1 Position2 Alleles3 Heterozygote OR 
(95% CI) 
Homozygote OR 
(95% CI) 
P value (2df) 
 
P for departure  
from log additivity 
Het P (Q) I2 
rs12405132 1 145644984 C/T 0.96 
(0.93-0.99) 
0.89 
(0.85-0.93) 
1.10x10-06 0.399 0.49 0 
rs12048493 1 149927034 A/C 1.06 
(1.03-1.10) 
1.16 
(1.10-1.23) 
1.03x10-08 0.517 0.15 18.87 
rs72755295 1 242034263 A/G 1.15 
(1.08-1.21) 
1.62 
(1.05-2.50) 
1.08x10-06 0.358 0.38 4.90 
rs6796502 3 46866866 G/A 0.93 
(0.9-0.97) 
0.73 
(0.62-0.85) 
7.50x10-07 0.049 0.46 0.38 
rs13162653 5 16187528 G/T 0.97 
(0.93-1.01) 
0.89 
(0.85-0.93) 
5.69x10-06 0.263 0.64 0 
rs2012709 5 32567732 C/T 1.05 
(1.01-1.09) 
1.11 
(1.06-1.16) 
1.03x10-05 0.916 0.12 21.03 
rs7707921 5 81538046 A/T 0.92 
(0.86-0.99) 
0.86 
(0.81-0.92) 
2.99x10-08 0.803 0.52 0 
rs9257408 6 28926220 G/C 1.05 
(1.02-1.09) 
1.11 
(1.06-1.16) 
2.93x10-06 0.898 0.04 30.15 
rs4593472 7 130667121 C/T 0.95 
(0.92-0.97) 
0.92 
(0.88-0.96) 
1.71x10-05 0.413 0.01 39.47 
rs13365225 8 36858483 A/G 0.94 
(0.92-0.97) 
0.93 
(0.85-1.01) 
0.000588 0.431 0.08 24.85 
rs13267382 8 117209548 G/A 1.06 
(1.02-1.11) 
1.11 
(1.06-1.16) 
2.24x10-05 0.471 0.95 0 
rs11627032 14 93104072 T/C 0.96 
(0.92-0.99) 
0.85 
(0.8-0.91) 
2.65x10-06 0.173 0.87 0 
chr17:29230520:D 17 29230520 GGT/G 0.93 
(0.90-0.96) 
0.89 
(0.82-0.97) 
5.55x10-06 0.489 0.13 20.26 
rs745570 17 77781725 A/G 0.96 
(0.93-0.99) 
0.9 
(0.87-0.94) 
2.46x10-06 0.547 0.59 0 
rs6507583 18 42399590 A/G 0.91 
(0.87-0.95) 
0.85 
(0.69-1.04) 
7.39x10-06 0.805 0.94 0 
 
1 Chromosome 
2 Build 37 position 
3 Reference/effect allele (forward strand). 
4 OR for heterozygotes relative to reference allele homozygotes 
5 OR for homozygotes relative to effect allele homozygotes 
6 P-value for heterogeneity in the per-allele ORs among the iCOGS studies (Q-statistic) 
7 I2 statistic for heterogeneity in the per-allele ORs among the iCOGS studies  
 
  
Supplementary Table 7: Per allele ORs for DCIS vs invasive disease (based on 2470 dcis and 44,791 invasive cases in the iCOGS dataset). 
 
Top variant Chr1 Position2 Alleles3 OR invasive 
(95% CI) 
P invasive OR dcis 
(95% CI)  
P dcis P invasive vs dcis 
rs12405132 1 145644984 C/T 0.95 
(0.93-0.97) 
1.22x10-07 0.97 
(0.91-1.03) 
0.313 0.796 
rs12048493 1 149927034 A/C 1.07 
(1.05-1.10) 
2.64x10-09 1.06 
(0.99-1.14) 
0.103 0.89 
rs72755295 1 242034263 A/G 1.16 
(1.1-1.23) 
1.08x10-07 1.02 
(0.86-1.21) 
0.856 0.416 
rs6796502 3 46866866 G/A 0.91 
(0.88-0.95) 
5.42x10-07 0.91 
(0.82-1.02) 
0.107 0.674 
rs13162653 5 16187528 G/T 0.95 
(0.93-0.97) 
3.18x10-06 0.95 
(0.89-1.02) 
0.183 0.938 
rs2012709 5 32567732 C/T 1.05 
(1.03-1.08) 
1.98x10-06 1.04 
(0.97-1.11) 
0.267 0.741 
rs7707921 5 81538046 A/T 0.93 
(0.91-0.95) 
1.28x10-08 0.93 
(0.86-1) 
0.054 0.645 
rs9257408 6 28926220 G/C 1.06 
(1.03-1.08) 
2.30x10-07 1.07 
(1-1.14) 
0.038 0.706 
rs4593472 7 130667121 C/T 0.95 
(0.93-0.97) 
2.67x10-06 0.97 
(0.91-1.03) 
0.316 0.546 
rs13365225 8 36858483 A/G 0.95 
(0.93-0.98) 
0.000356 0.92 
(0.85-1) 
0.054 0.502 
rs13267382 8 117209548 G/A 1.05 
(1.03-1.07) 
1.21x10-05 1.03 
(0.96-1.09) 
0.416 0.456 
rs11627032 14 93104072 T/C 0.94 2.91x10-06 0.9 0.007 0.183 
(0.92-0.96) (0.83-0.97) 
chr17:29230520:D 17 29230520 GGT/G 0.93 
(0.91-0.96) 
6.36x10-07 0.96 
(0.88-1.04) 
0.32 0.21 
rs745570 17 77781725 A/G 0.95 
(0.93-0.97) 
1.34x10-07 0.99 
(0.93-1.06) 
0.8 0.141 
rs6507583 18 42399590 A/G 0.91 
(0.88-0.95) 
2.43x10-06 0.91 
(0.81-1.03) 
0.13 0.939 
 
1 Chromosome 
2 Build 37 position 
3 Reference/effect allele (forward strand)
 Supplementary Table 8: Per-allele ORs for ER- vs. ER+ disease (based on 7333 ER- cases and 27,078 ER+ cases in the iCOGS dataset). 
 
Top variant Chr1 Position2 Alleles3 OR ER+  
(95% CI) 
P ER+ OR ER- 
(95% CI)  
P ER- P ER+/ER- 
rs12405132 1 145644984 C/T 0.93 
(0.91-0.96) 1.25x10-08 
0.98 
(0.94-1.02) 0.3386 
0.019 
rs12048493 1 149927034 A/C 1.09 
(1.06-1.12) 3.37x10-10 
1.02 
(0.98-1.06) 0.292 
0.010 
rs72755295 1 242034263 A/G 1.16 
(1.09-1.24) 4.04x10-06 
1.21 
(1.09-1.34) 0.0004 
0.599 
rs6796502 3 46866866 G/A 0.9 
(0.87-0.94) 1.25x10-06 
0.94 
(0.88-1.01) 0.0950 
0.070 
rs13162653 5 16187528 G/T 0.94 
(0.92-0.97) 1.75x10-05 
0.96 
(0.92-1) 0.0517 
0.388 
rs2012709 5 32567732 C/T 1.05 
(1.03-1.08) 7.27x10-05 
1.04 
(1-1.08) 0.0784 
0.684 
rs7707921 5 81538046 A/T 0.92 
(0.89-0.95) 5.00x10-09 
0.97 
(0.92-1.01) 0.1380 
0.062 
rs9257408 6 28926220 G/C 1.05 
(1.03-1.08) 5.07x10-05 
1.05 
(1.01-1.1) 0.0095 
0.867 
rs4593472 7 130667121 C/T 0.94 
(0.92-0.96) 3.57x10-07 
0.99 
(0.95-1.03) 0.6806 
0.046 
rs13365225 8 36858483 A/G 0.95 
(0.92-0.98) 0.00062 
0.93 
(0.88-0.98) 0.0034 
0.608 
rs13267382 8 117209548 G/A 1.05 
(1.02-1.07) 9.57x10-05 
1.06 
(1.02-1.1) 0.0043 
0.851 
rs11627032 14 93104072 T/C 0.95 
(0.92-0.98) 0.00077 
0.92 
(0.87-0.96) 0.0007 
0.426 
chr17:29230520:D 17 29230520 GGT/G 0.92 
(0.89-0.95) 1.43x10-06 
0.93 
(0.88-0.98) 0.008 
0.781 
rs745570 17 77781725 A/G 0.94 
(0.92-0.96) 4.02x10-07 
0.95 
(0.91-0.99) 0.0097 
0.691 
rs6507583 18 42399590 A/G 0.9 
(0.86-0.94) 7.60x10-06 
0.97 
(0.9-1.05) 0.4315 
0.036 
 
 
1 Chromosome 
2 Build 37 position 
3 Reference/effect allele (forward strand)   
Supplementary Table 9: Per-allele ORs by age at diagnosis ( age categories <40:  3987,40-50 : 9714, 50-60 :13,313 , >=60 : 15,176). 
 
Top variant Chr1 Position2 Alleles3 
 
Per-allele OR (95% CI) by age at diagnosis P-value for trend 
<40 40-49 50-59 60+  
rs12405132 1 145644984 C/T 0.96 
(0.91-1.01) 
0.94 
(0.9-0.97) 
0.96 
(0.93-0.99) 
0.94 
(0.92-0.97) 0.998 
rs12048493 1 149927034 A/C 1.07 
(1-1.13) 
1.11 
(1.07-1.15) 
1.06 
(1.02-1.09) 
1.07 
(1.04-1.10) 0.133 
rs72755295 1 242034263 A/G 1.21 
(1.05-1.39) 
1.19 
(1.09-1.31) 
1.13 
(1.05-1.22) 
1.16 
(1.08-1.25) 0.852 
rs6796502 3 46866866 G/A 0.91 
(0.84-1) 
0.88 
(0.83-0.94) 
0.91 
(0.87-0.96) 
0.93 
(0.89-0.98) 0.522 
rs13162653 5 16187528 G/T 0.89 
(0.84-0.95) 
0.93 
(0.9-0.97) 
0.94 
(0.91-0.97) 
0.96 
(0.93-0.99) 0.007 
rs2012709 5 32567732 C/T 1.04 
(0.98-1.1) 
1.05 
(1.01-1.09) 
1.05 
(1.02-1.08) 
1.05 
(1.02-1.08) 0.528 
rs7707921 5 81538046 A/T 0.96 
(0.9-1.02) 
0.9 
(0.86-0.94) 
0.95 
(0.91-0.98) 
0.92 
(0.89-0.95) 0.999 
rs9257408 6 28926220 G/C 1.01 
(0.96-1.07) 
1.06 
(1.02-1.09) 
1.04 
(1.01-1.07) 
1.07 
(1.04-1.1) 0.774 
rs4593472 7 130667121 C/T 0.97 
(0.92-1.02) 
0.95 
(0.92-0.99) 
0.94 
(0.92-0.97) 
0.96 
(0.93-0.98) 0.867 
rs13365225 8 36858483 A/G 0.9 
(0.84-0.96) 
0.96 
(0.91-1) 
0.93 
(0.9-0.97) 
0.97 
(0.94-1.01) 0.492 
rs13267382 8 117209548 G/A 1.06 
(1.01-1.12) 
1.08 
(1.05-1.12) 
1.05 
(1.02-1.08) 
1.04 
(1.01-1.07) 0.332 
rs11627032 14 93104072 T/C 0.93 0.93 0.95 0.94 0.464 
(0.87-0.99) (0.89-0.97) (0.92-0.99) (0.91-0.97) 
chr17:29230520:D 17 29230520 GGT/G 0.89 
(0.83-0.96) 
0.92 
(0.88-0.97) 
0.95 
(0.91-0.99) 
0.92 
(0.89-0.96) 0.52 
rs745570 17 77781725 A/G 0.95 
(0.91-1) 
0.95 
(0.92-0.98) 
0.95 
(0.92-0.98) 
0.96 
(0.93-0.99) 0.704 
rs6507583 18 42399590 A/G 1.02 
(0.92-1.12) 
0.92 
(0.86-0.98) 
0.91 
(0.86-0.96) 
0.88 
(0.84-0.93) 0.006 
 
1 Chromosome 
2 Build 37 position 
3 Reference/effect allele (forward strand)   
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